April 29, 2025

RNA-seq maps genetic, nongenetic drivers of AML

Investigators used RNA sequencing to create a new gene activity atlas that showed how normal blood cells developed. The technique.

Chronic Myeloid Leukemia Leukemia Podcast

For CML, the science is here now access must follow

Jerald Radich and Saad Usmani discusss chronic myeloid leukemia and research funding cuts on this SOHO Insider podcast episode.

Read More
Multiple Myeloma News

Early intervention with daratumumab for smoldering myeloma may delay disease progression

Researchers observed delayed progression to multiple myeloma (MM) in patients with smoldering MM (SMM) who were treated with single-agent daratumumab.

Read More
Lymphoma

EMA approves OT-C001 trial in DLBCL

The European Medicines Agency (EMA) has approved an Investigational Medicinal Product Dossier (IMPD) for OT-C001.

Read More
Acute Myeloid Leukemia Leukemia News

Triplet ‘effective’ in relapsed or refractory AML

A phase 2 study found that cladribine, idarubicin, and cytarabine (CLIA) was “effective” in treating relapsed or refractory acute myeloid.

Read More
Multiple Myeloma News

Real-world data support efficacy of IsaPd triplet in relapsed/refractory myeloma

A real-world, multicenter study supported findings from the pivotal ICARIA-MM clinical trial, showing that isatuximab, pomalidomide, and dexamethasone (IsaPd) was an.

Read More
Lymphoma Multiple Myeloma News

Spain’s POC manufacturing model reimagines CAR-T delivery

While the US relies on centralized, commercial CAR-T manufacturing, Spain is taking a different approach. At Hospital Clínic de Barcelona,.

Read More
News

SOHO announces new half-day CME program, leadership update

As SOHO continues to expand and connect with a growing global community, we remain focused on supporting hematologic oncologists through.

Read More
Lymphoma News

Early-phase trial shows promise for refractory CD30-positive lymphoma

A CD30/CD16A bispecific antibody, AFM13, “showed encouraging preliminary safety and efficacy

Read More
Aggressive B-Cell Lymphomas Lymphoma

ELM-1 cohort study assesses odronextamab after CAR-T therapy for DLBCL

Odronextamab monotherapy resulted in a 48.3% overall response rate in patients with diffuse large B-cell lymphoma (DLBCL) who had progressed.

Read More
Leukemia News

Pathways & Perspectives with Charles Craddock, CBE

Dr. Craddock talks life in general and about the past and future of blood cancer treatments.

Read More
News

Dr. Kidson-Gerber discusses guidelines for pregnant patients with blood cancers

Giselle Kidson-Gerber, FRACP, FRCPA, a hematologist and clinical researcher at Prince of Wales Hospital and the Royal Hospital for Women,.

Read More
Cellular Therapy

Early-phase study shows promise of novel CAR-T talicabtagene autoleucel for B-cell malignancies

The novel chimeric antigen receptor (CAR) T-cell therapy talicabtagene autoleucel induced durable responses in an Indian population with relapsed or.

Read More

Top Categories

POPULAR NEWS

Meetings

MEMBERS

Editorial Board

Members Strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:

Career

SOHO Career Center

The Career Center provides SOHO members with the ability to find jobs in the field of Hematologic Oncology along with a variety of career advice. Select the 'Career Center' button to explore new job opportunities and career information.

The Career Center Allows SOHO Members to:

To access the SOHO Career Center click the following link.

Verified by MonsterInsights